4D pharma PLC (LON: DDDD) (NASDAQ:LBPS) CEO Duncan Peyton tells Proactive the group passed a “transformational milestone” following the completion of its merger with investment vehicle Longevity Acquisition Corporation. Peyton says the transaction provides the UK group with a quote on the tech- and biotech-focused NASDAQ stock market and has raised $40M in capital, putting 4D in a 'great position' to advance its oncology and Parkinson's Disease programs.
4D Pharma begins trading shares on the Nasdaq following merger with Longevity
